Mankind Pharma Q2 profit jumps 29%; chronic segment outperforms
The company reported a stronger-than-expected profit, driven by high demand for its drugs for chronic conditions such as diabetes and cardiovascular diseases.
mankind pharma
November 2024
October 2024
September 2024
July 2024
May 2024
December 2023
Mankind Pharma shares end 8-session losing streak on acquisition of BSV
The pharma company has acquired 100% stake in Bharat Serums and Vaccines Ltd (BSV), which will be funded through a combination of internal accruals and external debt.
Mankind Pharma shares extend gain on CCI nod for BSV acquisition
The CCI has cleared Mankind Pharma's proposed acquisition of 100% stake in Bharat Serums and Vaccines for ₹13,630 crore.
Mankind Pharma shares snap 4-session losing streak on fundraising, OTC biz transfer
The pharma major has transferred its Over-the-Counter (OTC) business to its subsidiary, Mankind Consumer Products, via a slump sale.
Mankind Pharma board approves raising of ₹10,000 cr via private placement
Mankind Pharma's Q1 profit surged 10% YoY to ₹543 crore; brokerage Motilal Oswal expects 14% earnings CAGR over FY24-26
Mankind Pharma Q1 results: Profit rises 10% to ₹543 cr; revenue up 12%
The revenue from domestic business grew 9% YoY to ₹2,634 cr in Q1 FY25, while exports rose 62% YoY to ₹259 cr
Mankind Pharma buys 100% stake in BSV for ₹13,630 cr
The move marks a significant leap for Mankind Pharma, positioning it as a market leader in the Indian women's health and fertility drug market.
Budget paves way for India's healthcare transformation: Mankind Pharma
The budget demonstrates a strong commitment to the health sector's growth and development, says Arjun Juneja, Chief Operating Officer, Mankind Pharma
Mankind Pharma shares rise up to 5% on strong Q4, fundraising plan
The board of the homegrown pharma company has approved raising of funds worth ₹7,500 crore via issuance of equity shares.
Mankind Pharma shares skid 4% amid block deal buzz
Three private equity funds, namely Chrys Capital, Capital Group, and Everbridge Partners, were reportedly looking to sell stakes worth $592 million in Mankind Pharma via the block deal.
